In conversation with...

Editor Helen Frankish discusses highlights from the May issue: results from the INTERACT trial showing how intensive blood pressure lowering could be beneficial for people who have had intra cranial haemorrhage; also discussion of a genetic study identifying a gene mutation involved in amyloid lateral sclerosis, and a review of stroke in children.

Editor Helen Frankish discusses highlights from the April issue: including the EPITHET study of alteplase treatment 3-6 hours after a stroke, and donepezil treatment in patients with CADASIL, a genetic form of vascular dementia.

Editor Helen Frankish discusses highlights from the March issue: including research Articles about a genetic clue to the cause of dystonia, a neurological disorder relating to Parkinson's disease; and a study identifying older age (68 years) as a risk factor for stroke among people given stenting rather than Endarterectomy to unblock the carotid artery.

Imaging of amyloid β in Alzheimer's disease with a novel PET tracer Amyloid β (Aβ) deposits can be imaged by PET, but most Aβ PET ligands are not suitable for clinical diagnosis of Alzheimer's disease (AD). To test the effectiveness of a new Aβ PET ligand, 18F-BAY94-9172, Christopher Rowe and colleagues compared its binding with Aβ deposition in patients with AD, individuals with frontotemporal lobar degeneration, and healthy controls. Helen Frankish discusses the study in this month's podcast, and highlights the editorial concerning the possible tagging of individuals with AD.

Epilepsy in children encompasses several syndromes that have different prognoses but are all characterised by a predisposition to recurrent seizures; therefore, treatment has to be tailored to the individual. Any treatment regimen for children with epilepsies should have rational goals, take into account the additional morbidities that are commonly found in these patients.